
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health has demonstrated strong growth potential, notably with a reported 70% year-over-year subscriber growth in the fourth quarter, which bodes well for continued revenue growth as the company adjusts for shipping headwinds. The company's international expansion, now including the UK market and integration of Zava, is contributing incremental growth while diversifying revenue streams beyond their core specialties. Furthermore, Hims' strategic positioning to capitalize on weight-loss drug developments and the expansion of its service offerings mitigates concentration risk, ensuring a more stable financial outlook as they navigate through their business transition.
Bears say
Hims & Hers Health's outlook has been downgraded due to a significant slowdown in revenue growth, highlighted by disappointing fourth-quarter 2025 earnings and weak first-quarter 2026 guidance. Revenue estimates for 2027 have been revised down from $3.7 billion and $535 million in EBITDA to $3.1 billion and $404 million, respectively, reflecting a considerable decline in expected performance. Additionally, the company faces increased legal and regulatory risks, compounding the challenges posed by its anticipated lower-than-expected performance for the upcoming fiscal year.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares